聚焦艾昆纬-比利时抗肥胖药物的转变(英)-2026。Despite similar obesity prevalence across genders,women represent ~70% of AOM users, probably due to higher commitment due to prior weight-loss attempts.A. Prescriber uptake (for obesity use) of AOM since their launch B. Prescriber growth after tirzepatide launch Rest 27%。
聚焦艾昆纬-比利时抗肥胖药物的转变(英)-2026。Despite similar obesity prevalence across genders,women represent ~70% of AOM users, probably due to higher commitment due to prior weight-loss attempts.A. Prescriber uptake (for obesity use) of AOM since their launch B. Prescriber growth after tirzepatide launch Rest 27%。
聚焦艾昆纬-比利时抗肥胖药物的转变(英)-2026。Despite similar obesity prevalence across genders,women represent ~70% of AOM users, probably due to higher commitment due to prior weight-loss attempts.A. Prescriber uptake (for obesity use) of AOM since their launch B. Prescriber growth after tirzepatide launch Rest 27%。
覆盖 2026 年,全文约 27。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了药物、艾昆纬、比利时抗肥胖药物的转变等议题。